TCRT · XBRL financial data
Alaunos Therapeutics financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (TCRT's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 0 | 398 | 2,922 | 5 | 10 | 5 |
| Research and development | 52,696 | 49,643 | 25,018 | 16,279 | 362 | 1,363 |
| General and administrative | 27,665 | 27,564 | 13,142 | 12,219 | 4,460 | 2,867 |
| Total operating expenses | 80,361 | 77,947 | 38,027 | 34,272 | 4,822 | 4,230 |
| Operating income (loss) | (80,361) | (77,549) | (35,105) | (34,267) | (4,812) | (4,225) |
| Interest expense | — | 1,189 | 3,154 | 1,921 | 0 | — |
| Other income (expense) | 385 | (1,202) | 529 | 1,048 | 133 | 80 |
| Income tax expense (benefit) | — | — | — | — | — | 0 |
| Net income (loss) | (79,976) | (78,751) | (37,730) | (35,140) | (4,679) | (4,176) |
| Earnings per share, basic USD per share | (0.38) | (0.37) | (0.17) | (2.20) | (2.92) | (2.20) |
| Earnings per share, diluted USD per share | (0.38) | (0.37) | (0.17) | (2.20) | (2.92) | (2.20) |
| Weighted average shares, basic thousands of shares | 209,636 | 214,399 | 217,130 | 15,995 | 1,601 | 1,948 |
| Weighted average shares, diluted thousands of shares | 209,636 | 214,399 | 217,130 | 15,995 | 1,601 | 1,948 |
- † Share count changed about 1/15 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/10 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (TCRT's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 115,069 | 76,054 | 39,058 | 6,062 | 1,091 | 1,385 |
| Prepaid and other current assets | 10,855 | 1,666 | 799 | 2,198 | 1,659 | 600 |
| Total current assets | 130,589 | 78,831 | 53,799 | 8,261 | 2,755 | 1,988 |
| Property and equipment, net | 10,231 | 10,941 | 8,460 | 2 | 0 | 91 |
| Right-of-use asset | 4,650 | 4,420 | 2,136 | 0 | — | — |
| Total assets | 146,345 | 94,865 | 64,937 | 8,263 | 2,755 | 2,966 |
| Accounts payable | 960 | 1,368 | 1,389 | 616 | 516 | 613 |
| Accrued liabilities | 16,589 | 6,076 | 5,454 | 1,340 | 176 | 200 |
| Current portion of long-term debt | 0 | 7,868 | 16,765 | 0 | — | — |
| Total current liabilities | 18,368 | 16,041 | 24,166 | 1,956 | 692 | 813 |
| Long-term debt | 0 | 16,250 | 0 | 0 | 0 | — |
| Lease liability, non-current | 3,995 | — | — | — | — | — |
| Total liabilities | 22,363 | 36,809 | 26,382 | 1,956 | 692 | 813 |
| Accumulated deficit | (764,101) | (842,852) | (880,627) | (915,767) | (920,446) | (924,622) |
| Total stockholders' equity | 123,982 | 58,057 | 38,555 | 6,307 | 2,063 | 2,153 |
| Total liabilities and equity | 146,345 | 94,865 | 64,937 | 8,263 | 2,755 | 2,966 |
| Common shares outstanding (cover page) thousands of shares | 214,667 | 216,127 | 240,627 | 16,012 | 1,601 | 2,378 |
- † Share count changed about 1/15 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/10 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (TCRT's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (79,976) | (78,751) | (37,730) | (35,140) | (4,679) | (4,176) |
| Stock-based compensation | 6,829 | 10,774 | 3,528 | 2,800 | 435 | 796 |
| Net cash from operating activities | (57,013) | (61,468) | (29,232) | (30,142) | (4,971) | (2,869) |
| Purchases of property and equipment | 9,778 | 3,323 | 216 | 197 | 0 | 98 |
| Net cash from investing activities | (9,778) | (3,323) | (193) | 1,346 | 0 | (98) |
| Proceeds from issuing common stock | — | 0 | 14,724 | 92 | 0 | — |
| Share repurchases | — | 0 | 45 | 0 | — | — |
| Proceeds from long-term debt | 0 | 25,000 | 0 | — | — | — |
| Repayments of long-term debt | — | 0 | 8,333 | 18,105 | 0 | — |
| Net cash from financing activities | 102,119 | 25,776 | 6,367 | (18,138) | 0 | 3,261 |
| Net change in cash | 35,328 | (39,015) | (23,058) | (46,934) | (4,971) | 294 |
- † Share count changed about 1/15 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/10 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Alaunos Therapeutics | 124 | 0 | (300)* | 2.5M | 0.4 quarters | 10-QJun 30, 2026 |
| BioCardia | 4,117 | not reported | (1,735)* | 15.1M | 2.4 quarters | 10-QJun 30, 2026 |
| Raphael Pharmaceutical | 1 | not reported | 0* | 20.2M | — | 10-QJun 30, 2026 |
| Traws Pharma | 5,016 | not reported | (7,504)* | 15.4M | 0.7 quarters | 10-QJun 30, 2026 |
| Mannatech | 6,034 | 26,650 | (792)* | 1.9M | 7.6 quarters | 10-QJun 30, 2026 |
| Bioxytran | 177 | not reported | (350)* | 114.7M | 0.5 quarters | 10-QJun 30, 2026 |
| LeonaBio | 32,323 | not reported | (16,958)* | 9.4M | 3.0 quarters | 10-QJun 30, 2026 |
| Artelo Biosciences | 4,198 | not reported | (5,033)* | 4.6M | 0.8 quarters | 10-QJun 30, 2026 |
| Oncotelic Therapeutics | 186 | 250 | (92)* | 457.5M | 2.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.